A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis
Aim: To compare the safety and efficacy of antidepressants (AD) among older adults with major depressive disorder (MDD) by assessing treatment change, augmentation and hospitalization rates. Methods: This retrospective study analyzed data from the Veterans Affairs (VA) database, including 142,138...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-01-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim: To compare the safety and efficacy of antidepressants (AD) among older adults with major depressive
disorder (MDD) by assessing treatment change, augmentation and hospitalization rates. Methods:
This retrospective study analyzed data from the Veterans Affairs (VA) database, including 142,138
patients aged ≥60 years diagnosed with MDD. Patients prescribed bupropion, citalopram, duloxetine,
escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, or venlafaxine were included. Outcomes
were treatment change, augmentation and hospitalization rates. Hazard ratios (aHRs) were calculated
using sertraline as the reference. Results: Of the patients, 39.6% required augmentation, 18.1% changed
antidepressant treatment and 13.3% were hospitalized. The corresponding incidence rate was 544, 124
and 122 events per 1000 person-years. Compared with sertraline, mirtazapine users had the highest AD
change risk (aHR 1.34, 95% CI: 1.29–1.40), while duloxetine users had the lowest (aHR 0.87, 95% CI:
0.83–0.92). Duloxetine also had the lowest augmentation risk (aHR 0.89, 95% CI: 0.86–0.92). Mirtazapine
users also had the highest risks of augmentation (aHR 1.15, 95% CI: 1.12–1.18) and hospitalization (aHR
1.14, 95% CI: 1.07–1.23). Bupropion had the lowest hospitalization risk (aHR 0.77, 95% CI: 0.71–0.84).
Conclusion: Antidepressant choice significantly influences treatment outcomes in older adults with MDD.
Duloxetine demonstrated the best profile with the lowest risks of AD change and augmentation, while
mirtazapine posed the highest risks of all three outcomes. Personalized treatment strategies are crucial
to improving outcomes in this population. |
|---|---|
| ISSN: | 2042-6313 |